Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Progressive Castration-resistant Prostate Cancer”

61 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 61 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04946370
What this trial is testing

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT03725761
What this trial is testing

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 31
Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Early research (Phase 1)Study completedNCT03074032
What this trial is testing

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Avionco LLC 17
Large-scale testing (Phase 3)Looking for participantsNCT04876651
What this trial is testing

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Ltd 392
Testing effectiveness (Phase 2)Study completedNCT01091103
What this trial is testing

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Who this might be right for
Metastatic Progressive Castration-resistant Prostate Cancer
Pfizer 60
Testing effectiveness (Phase 2)Study completedNCT00005848
What this trial is testing

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Fox Chase Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02814968
What this trial is testing

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
The European Uro-Oncology Group 66
Testing effectiveness (Phase 2)Study completedNCT03392428
What this trial is testing

A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Cancer of the ProstateMetastatic Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 201
Testing effectiveness (Phase 2)Active Not RecruitingNCT03042468
What this trial is testing

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT02881242
What this trial is testing

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
Jonsson Comprehensive Cancer Center 14
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Study completedNCT02225704
What this trial is testing

Radium-223 in Combination With Enzalutamide

Who this might be right for
Prostate Cancer
Cancer Trials Ireland 45
Testing effectiveness (Phase 2)UnknownNCT01296243
What this trial is testing

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Genta Incorporated 57
Large-scale testing (Phase 3)Study completedNCT01707966
What this trial is testing

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Who this might be right for
Prostate Cancer
Swiss Cancer Institute 47
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Testing effectiveness (Phase 2)Looking for participantsNCT05114746
What this trial is testing

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Testing effectiveness (Phase 2)Study completedNCT02445976
What this trial is testing

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Who this might be right for
Prostate Cancer
Innocrin Pharmaceutical 197
Load More Results